Study: Real-world results of GLP-1 drugs don't match trials
Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and Zepbound aren't as impressive as those promised by the drugs' clinical trials, a new study says.
People taking such GLP-1 drugs lost just under 9% of their body weight on average after a year, researchers reported Tuesday in the journal Obesity.
That's far less than the 15% to 21% body weight reduction promised by the clinical trials that led to the approval of Wegovy (semaglutide) and Zepbound (tirzepatide) for weight loss, researchers said.
"Patients treated for obesity with semaglutide or trizepatide lost less weight on average in a regular clinical setting compared to what is observed in randomized clinical trial," lead investigator Hamlet Gasoyan said in a news release. He is a researcher at the Cleveland Clinic Center for Value-Based Care Research.
People taking the drugs in real-world settings appear to be more likely to quit taking the meds, researchers said. They also might be prescribed lower dosages in clinical practice than were used in the drug trials.
Glucagon-like peptide-1 (GLP-1) drugs mimic the GLP-1 hormone, which helps control insulin and blood sugar levels, decreases appetite and slows digestion of food.
For this study, researchers tracked nearly 7,900 patients being treated by the Cleveland Clinic for severe obesity, of whom about 6,100 were prescribed semaglutide and the rest tirzepatide.
Average body weight loss after a year was nearly 9% for the whole group, results show.
But weight loss varied based on when a person stopped taking the drugs, researchers found.
Average weight loss was under 4% for those who stopped treatment early, versus nearly 7% or those who stopped later on, the study says. Those who stayed on their medications lost an average 12% body weight.
Results also show that more than 4 in 5 (81%) of patients were prescribed a low maintenance dose of their GLP-1 drug, and that made a difference as well.
People who stayed on their meds and received high doses lost nearly 14% of their body weight with semaglutide and 18% with tirzepatide.
"Our findings about the real-world use patterns of these medications and associated clinical outcomes could inform the decisions of health care providers and their patients on the role of treatment discontinuation and maintenance dosage in achieving clinically meaningful weight reductions," Gasoyan said.
Overall, patients had higher odds of losing 10% or more of their body weight after a year if they remained on their meds, were prescribed a high dosage, were taking tirzepatide rather than semaglutide, and were female, results show.
The cost of the drugs and problems were insurance were a common reason for patients stopping GLP-1 treatment, along with side effects and medication shortages, researchers said.
Staying on the GLP-1 meds particularly helped the nearly 17% of patients who had prediabetes, a condition in which elevated blood sugar levels increase a person's risk of developing Type 2 diabetes.
About 68% of those who stuck with their treatment wound up with normal blood sugar levels, compared with 41% who stopped taking the drugs later in the study and 33% who stopped earlier.
"Type 2 diabetes is one of the most common complications of obesity, so diabetes prevention is very important," Gasoyan said. "This study highlights that treatment discontinuation, especially early, negatively affects both weight and glycemic control outcomes."
A follow-up study is in the works to better track why patients stop taking their GLP-1 drugs, researchers said.
More information
Harvard Medical School has more on GLP-1 drugs.
Copyright © 2025 HealthDay. All rights reserved.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Novo Nordisk plans to start late-stage trials of obesity drug amycretin next year
(Reuters) -Novo Nordisk said on Thursday it plans to start late-stage trials of its experimental weight-loss drug, amycretin, in injection and oral forms during the first quarter of 2026 for adults who are overweight or obese. The decision to advance the trials is based on feedback received from regulatory authorities in interactions following the end of its mid-stage trials, the company said. Amycretin, the Danish drugmaker's next-generation obesity drug, has a dual-mode action. Like its popular weight-loss drug Wegovy, amycretin not only mimics the gut hormone GLP-1, but also the effect of a hunger-suppressing pancreatic hormone called amylin. Weekly injections of the drug helped patients lose 22% of their weight in 36 weeks, according to early-stage trial results published in January. Last year, the pill version helped patients lose up to 13.1% of their weight after 12 weeks in early-stage trial. Novo is also developing another two-drug combination, known as CagriSema, which, too, targets the amylin hormone. The company has launched a new late-stage trial for the drug, the U.S. government's trial database showed this week, as it tries to reassure the market of its potential after disappointing data from two previous studies. Novo had positioned CagriSema as a more potent successor to its blockbuster obesity treatment Wegovy, but lower-than-expected weight loss stoked worries that Eli Lilly may be gaining an edge over the company in the market for such drugs.
Yahoo
2 hours ago
- Yahoo
Bernie Sanders, Angus King Propose Drug Advertising Ban in Consumer Marketing
Sens. Bernie Sanders and Angus King have introduced new legislation that would ban prescription drug advertising on television, radio, print, digital platforms and social media. The bill, known as the End Prescription Drug Ads Now Act, would apply to all drugs and biologics, including those currently on the market. 'With the exception of New Zealand, the United States is the only country in the world where it is legal for pharmaceutical companies to advertise their drugs on television. It is time for us to end that international embarrassment,' Sanders said in a statement. 'The American people don't want to see misleading and deceptive prescription drug ads on television. They want us to take on the greed of the pharmaceutical industry and ban these bogus ads.' The lawmakers note that the 10 largest drug companies made more than 100 billion in profits last year, with the pharmaceutical industry spending over $5 billion on television ads. They added that prescription drug commercials account for more than 30% of commercial time on major networks' evening news programs and that Big Pharma spent over $725 million advertising just 10 drugs in the first three months of 2025. Additionally, the pair noted that the prices for drugs in the U.S. are among the highest in the world, with one in four Americans not able to afford the costs of the medicine their doctors prescribe. For example, Novo Nordisk charges nearly $1,000 a month for Ozempic in the United States, compared to $59 in Germany, $71 in France, $122 in Denmark, and $155 in Canada, and $1,349 a month for Wegovy, compared to $92 in the United Kingdom, $137 in Germany, $186 in Denmark and $265 in Canada. 'The widespread use of direct-to-consumer advertising by pharmaceutical companies drives up costs and doesn't necessarily make patients healthier,' King added. 'The End Prescription Drug Ads Now Act would prohibit direct-to-consumer advertising of pharmaceutical drugs to protect people. This bill is a great step to ensure that patients are getting the best information possible and from the right source: their providers and not biased advertisements.' The introduction of the End Prescription Drug Ads Now Act follows repeated calls from Health and Human Services Secretary Robert F. Kennedy Jr. calling for a ban on prescription drug advertising. The Campaign for Sustainable Rx Pricing estimates that prohibiting pharmaceutical advertising could increase federal tax revenues by $1.5 to $1.7 billion annually from 10 of the largest pharmaceutical companies operating in the U.S. In addition to Sanders and King, cosponsors of the legislation include Democratic Sens. Chris Murphy, Peter Welch, Jeff Merkley and Dick Durbin. More to come… The post Bernie Sanders, Angus King Propose Drug Advertising Ban in Consumer Marketing appeared first on TheWrap.
New York Post
3 hours ago
- New York Post
Ozempic use among teens is skyrocketing — and parents are getting a stern warning from experts
It's the hot-shot fix that took Hollywood — and now high school — by storm. Ozempic and other so-called 'miracle' weight-loss meds are being prescribed to teens in record numbers, with prescriptions among 12- to 17-year-olds jumping 50% in 2024, according to Truveta. Another study from the Evernorth Research Institute, as reported by Reuters, clocked a whopping 68% rise in use among adolescents overall. Advertisement But while slim-down shots like Wegovy may shrink waistlines, some experts say parents should pump the brakes — before turning their kids into pin cushions. Dr. Robert Siegel, a pediatrician at Cincinnati Children's Hospital, didn't mince words, telling the news agency, 'These medications are likely to be needed for a very long time to maintain weight.' He added that 'we only have a relatively short-term experience with them.' Advertisement In other words, we've barely scratched the surface on what these meds might do to growing bodies — and kids could be stuck on them for life. The spike in teen prescriptions comes after Wegovy was approved for adolescents in late 2022. Since then, families desperate to beat back the obesity epidemic — which affects 1 in 4 American teens — have turned to GLP-1 meds in growing numbers. 'It's promising that more young people are using these medications, but it's still a very small percentage of patients with severe obesity that are getting access to them,' Dr. Cate Varney, director of obesity medicine at the University of Virginia Health system, told Reuters. Advertisement Experts warn we're rolling the dice — these shots could mess with growing bodies, and kids might be stuck jabbing themselves for life. nuzza11 – 'When lifestyle changes alone are insufficient, we need these additional tools.' Still, the new tools come with plenty of fine print. 'The medications may need to be used indefinitely,' Siegel said, noting most pediatricians don't have the training — or equipment — to track long-term effects like muscle loss or developmental delays. Advertisement Novo Nordisk, the maker of Ozempic and Wegovy, insists there's no reason to panic. Slim-down shots might melt fat fast — but docs say teens should ditch the syringes and stick to sweat, not semaglutide, for lasting results. Corbis via Getty Images The company said in a statement that semaglutide 'did not appear to affect growth or pubertal development' in teen clinical trials. 'We are confident in the proven safety and efficacy of our GLP-1 medicines,' Novo added. Eli Lilly, whose drug Zepbound is in trials for teen use, echoed that stance, as per Reuters. 'There has been no evidence to date suggesting impairment in growth or metabolism,' the company said. But that's not enough to calm critics. U.S. Health Secretary Robert F. Kennedy Jr. slammed the trend as a sign of the 'overmedicalization of our kids,' citing a lack of long-term safety data and possible threats to metabolism and development. Advertisement With weight-loss shots looking more like a long-haul commitment than a quick fix, some doctors say teens should focus on old-school strategies before turning to syringes. As The Post previously reported, a survey from digital healthcare platform Tebra found that 37% of young Americans in this age group are planning to ditch the gym and head to the pharmacy instead — turning to Ozempic, Wegovy and other GLP-1 drugs to hit their weight-loss goals. While Gen Z is the most eager to jump on the injection bandwagon, older folks are actually more confident in the drugs' effectiveness — with 72% of baby boomers saying they work better than traditional methods. Still, the craze has a dark side: Some users have turned to shady, even dangerous methods, including counterfeit meds and unprescribed use, triggering new fears about addiction and a lack of proper oversight.
